Ranee Mehra, MD

Ranee Mehra, MD, highlights developments and ongoing questions regarding the evolving treatment paradigm for patients with head and neck cancer.

Ranee Mehra, MD, highlights how the ongoing OrigAMI-5 study may address an unmet need for patients with treatment-naive, recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the design of the OrigAMI-5 trial of pembrolizumab plus amivantamab and carboplatin for recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the toxicities associated with subcutaneous amivantamab in recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the efficacy of subcutaneous amivantamab plus pembrolizumab in patients with first-line recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the FDA breakthrough therapy designation for amivantamab and hyaluronidase for patients with recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses long-term follow-up data from the phase 2 E3311 trial in patients with HPV-associated oropharynx cancer.

Ranee Mehra, MD, discusses long-term results for primary transoral surgery followed by reduced postoperative radiation in HPV-associated oropharynx cancer.

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes